Literature DB >> 9551818

Development and validation of a sensitive method for the determination of ganciclovir in human plasma samples by reversed-phase high-performance liquid chromatography.

M A Campanero1, B Sadaba, E García-Quetglas, J R Azanza.   

Abstract

A rapid, sensitive, specific liquid chromatographic method has been developed for the determination of therapeutic levels of ganciclovir in human plasma. Plasma (1 ml) and acyclovir (I.S.) were treated with 50% trichloroacetic acid. The supernatant was neutralized with 2 M NaOH and purified with chloroform. The aqueous phase (80 microl) was analyzed by a 3-microm Hypersil ODS C18 column with 0.04 M triethylamine-0.1 M sodium dihydrogen phosphate monohydrate as the mobile phase (1 ml/min) and ultraviolet detection at 254 nm. Calibration was linear from 50 to 10000 ng/ml. Intra- and inter-day C.V. did no exceed 6.65%. The detection limit was about 10 ng/ml.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9551818     DOI: 10.1016/s0378-4347(97)00666-x

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  3 in total

1.  Monitoring of trough plasma ganciclovir levels and peripheral blood cytomegalovirus (CMV)-specific CD8+ T cells to predict CMV DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients.

Authors:  Estela Giménez; Carlos Solano; José Ramón Azanza; Paula Amat; David Navarro
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

2.  Improved intraocular bioavailability of ganciclovir by mucoadhesive polymer based ocular microspheres: development and simulation process in Wistar rats.

Authors:  Usha Ganganahalli Kapanigowda; Sree Harsha Nagaraja; Balakeshwa Ramaiah; Prakash Rao Boggarapu
Journal:  Daru       Date:  2015-10-24       Impact factor: 3.117

3.  Antiviral Drug Ganciclovir Is a Potent Inhibitor of the Proliferation of Müller Glia-Derived Progenitors During Zebrafish Retinal Regeneration.

Authors:  Shuqiang Zhang; Zhaoxia Mu; Chunjiao He; Minmin Zhou; Dong Liu; Xiao-Feng Zhao; Daniel Goldman; Hui Xu
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-04-01       Impact factor: 4.799

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.